Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,555   +0,001   (+0,18%) Dagrange 0,542 - 0,582 266.489  

Novacyt de volgende biotech raket!

Volgen
70.773 Posts
Pagina: «« 1 2 3 4 5 6 ... 3539 »» | Laatste | Omlaag ↓
  3. [verwijderd] 16 augustus 2017 11:44
    And the reaction is there to see +13.51% so far

    I think it is the beginning of the turn for novacyt.

    Maybe another conversion of those convertible bonds to raise cash by year-end but from 2018 cash flow should be positive.

    and also profit making...
    One to leave alone for a number of years I think
  8. [verwijderd] 3 oktober 2017 11:53
    Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces the appointment of Paul Eros as Commercial Director of Primerdesign, effective from 1 November 2017.

    Paul has over thirty years’ of experience within the field of molecular diagnostics, including strategic global marketing, sales and product management. He joins Novacyt from DiaSorin, where he was Vice President of Molecular Marketing for over five years. Paul started his career with Becton Dickinson, quickly progressing through the sales and marketing organisation in both the UK and France, before joining Roche Diagnostics in 1999, where he held a number of senior international commercial and operational roles.

    Paul’s appointment completes Novacyt’s investment in its senior commercial leadership team, building on the earlier Group appointments of Ruth Powell and Phil Sefton. Ruth Powell was appointed as Managing Director of the NovaPrep® division and Phil Sefton as Managing Director of Lab21 Products division.

    Momentum within the Primerdesign business continues to build, driven by the strength of the commercial pipeline and increasing breadth of the molecular product offering. In addition, Primerdesign has increased its focus on building its business-to-business (“B2B”) pipeline which is developing well. Management expect this new vertical to form a significant part of future revenues and its first three B2B design prototyping and development contracts have recently been secured for delivery in Q4 2017.

    Graham Mullis, Group CEO of Novacyt, commented:

    “We are delighted to welcome Paul to the Company at this important juncture in our growth. We have made significant progress growing our business-to-business channel in Primerdesign and have already signed three new design prototyping and development contracts for Q4 2017. Paul’s considerable blue-chip commercial expertise specifically in molecular diagnostics will be hugely beneficial as we aim to convert our healthy pipeline of clinical projects and B2B opportunities into new contracts. We remain committed to investing in commercial expansion and I have been pleased with the important and early positive impact that Ruth and Phil have already made to the Group. I am confident that we have invested in a strong senior leadership team that can continue to drive growth from the many opportunities that we see.”
  12. [verwijderd] 18 oktober 2017 18:09
    Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces that it has raised a total of €9.7 million (before expenses) through a conditional placing (the "Placing”) of 7,051,590 new shares (the "Placing Shares”), raising €4.7 million, and through an unconditional direct subscription (the "Subscription”) of 7,687,989 new shares (the "Subscription Shares”), raising €5.0 million, both at an issue price of 59.38 pence (€0.66) per share (the "Issue Price”) with support from new UK institutional investors and both new and current French institutional investors.
  13. [verwijderd] 18 oktober 2017 18:11
    In addition, the Company announces the publication of its AIM admission document and its intention to obtain a dual-listing by applying for the admission of the Company’s issued and to be issued shares (the "Enlarged Share Capital”) to trading on AIM, a market operated by the London Stock Exchange ("AIM Admission”).

    The first tranche of Subscription Shares, representing gross funds raised of €5.0 million, has been unconditionally issued and admission of these shares is expected to become effective on Euronext Growth Paris on 19 October 2017, unconditional on AIM Admission. The balance of Subscription Shares and all Placing Shares, representing gross funds raised of €4.7 million, are expected to be issued on 1 November 2017, with AIM Admission becoming effective and dealings in the Enlarged Share Capital commencing on AIM on 1 November 2017.
  16. [verwijderd] 19 oktober 2017 11:15
    quote:

    wieweet schreef op 18 oktober 2017 21:58:

    Dus nu instappen...? Kijk even morgen vroeg of de koers nog iets gaat dalen anders vol erin...hmmmm of maar een beetje?

    vrgr
    If you have not yet and with such deep discount you could definitely go for it.

    The company is now assured of its funding for quite awhile.
    With the second listing it will attract more interest with additional UK investors who will no longe have the potential currency risk

    It might take a few months of course or at least until financial figures come out.
    We shall see ...
  17. [verwijderd] 31 oktober 2017 23:21
    Morgen eerste handelsdag in Londen.
    Ben benieuwd hoeveel volume dat geeft.
    Hopelijk kan het wat positief sentiment brengen.

    Al met al ben ik positief over deze operatie.
    Ondanks dat de uitgifte-prijs erg tegenviel.
    Het opgehaalde bedrag viel me erg mee, en gezien de volumes en koersverloop is bijna alles in vaste handen terecht gekomen.

    Geen idee wat er morgen gaat gebeuren, maar het kan bijna niet anders dat het een keer flink gaat bouncen.
70.773 Posts
Pagina: «« 1 2 3 4 5 6 ... 3539 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee